1
|
Gao J, Zhou J, Zhang M, Zhang Y, Zeng Y, Li S, Xu K, Yao R. A novel 2-iminobenzimidazole compound, XYA1353, displays in vitro and in vivo anti-myeloma activity via targeting NF-κB signaling. Mol Cell Biochem 2024; 479:843-857. [PMID: 37204666 DOI: 10.1007/s11010-023-04764-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Accepted: 05/07/2023] [Indexed: 05/20/2023]
Abstract
Multiple myeloma (MM) is an accumulated disease of malignant plasma cells, which is still incurably owing to therapeutic resistance and disease relapse. Herein, we synthesized a novel 2-iminobenzimidazole compound, XYA1353, showing a potent anti-myeloma activity both in vitro and in vivo. Compound XYA1353 dose-dependently promoted MM cell apoptosis via activating caspase-dependent endogenous pathways. Moreover, compound XYA1353 could enhance bortezomib (BTZ)-mediated DNA damage via elevating γH2AX expression levels. Notably, compound XYA1353 interacted synergistically with BTZ and overcame drug resistance. RNA sequencing analysis and experiments confirmed that compound XYA1353 inhibited primary tumor growth and myeloma distal infiltration by disturbing canonical NF-κB signaling pathway via decreasing expression of P65/P50 and p-IκBα phosphorylation level. Due to its importance in regulating MM progression, compound XYA1353 alone or combined with BTZ may potentially exert therapeutic effects on multiple myeloma by suppressing canonical NF-κB signaling.
Collapse
Affiliation(s)
- Jian Gao
- School of Medicine, Anhui University of Science and Technology, Huainan, China
| | - Jian Zhou
- Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
| | - Menghui Zhang
- Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
| | - Yan Zhang
- Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
| | - Yindi Zeng
- Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
| | - Shihao Li
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, China
| | - Kailin Xu
- Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.
| | - Ruosi Yao
- Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Xuzhou Ruihu Health Management and Consulting Co., Ltd, Xuzhou, Jiangsu, China.
| |
Collapse
|
2
|
Dutta RP, Kumar R, Tembhare PR, Bagal B, Swain RK, Hasan SK. Targeting transcriptional kinase of CDK7 halts proliferation of multiple myeloma cells by modulating the function of canonical NF-kB pathway and cell cycle regulatory proteins. Transl Oncol 2023; 35:101729. [PMID: 37369156 DOI: 10.1016/j.tranon.2023.101729] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Revised: 06/17/2023] [Accepted: 06/20/2023] [Indexed: 06/29/2023] Open
Abstract
Multiple myeloma (MM) is an incurable plasma cell neoplasm. Despite several effective frontline therapeutic regimens, including Bortezomib (BTZ), relapse is almost inevitable; therefore, better therapeutic modalities to improve the outcomes are needed. Cyclin-dependent kinases (CDKs) are an essential constituent of the cellular transcriptional machinery and tumors including MM are critically dependent on transcription to maintain their oncogenic state. In the present study, we explored the efficacy of THZ1, a covalent CDK7 inhibitor in MM treatment using Bortezomib resistant (H929BTZR) cells and zebrafish xenografts. THZ1 showed anti-myeloma activity in the models of MM but had no effect on healthy CD34+ cells. THZ1 suppresses phosphorylation of carboxy-terminal domain of RNA polymerase II and downregulates the transcription of BCL2 family of proteins both in H929BTZS and H929BTZR cells leading to G1/S arrest and apoptosis. THZ1 mediates inhibition of bone marrow stromal cells-induced proliferation and activation of NF-kB signaling. The data derived from zebrafish xenografts of MM demonstrate that THZ1 combined with BTZ synergistically reduces tumor growth in zebrafish embryos. Collectively, our results reveal that THZ1 alone as well as in combination with BTZ has effective anti-myeloma activity.
Collapse
Affiliation(s)
- Rudra Prasad Dutta
- Hasan Lab, ACTREC-Tata Memorial Centre, Mumbai, India; Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, NY, USA
| | - Rohit Kumar
- Hasan Lab, ACTREC-Tata Memorial Centre, Mumbai, India; Department of Medicine, Baylor College of Medicine, Houston, TX, USA
| | | | - Bhausaheb Bagal
- Adult Hematolymphoid Disease Management Group, Department of Medical Oncology, Tata Memorial Centre, Mumbai, India
| | - Rajeeb Kumar Swain
- Developmental Biology, Institute of Life Sciences, Bhubaneswar, Bhubaneswar, India
| | - Syed Khizer Hasan
- Hasan Lab, ACTREC-Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, Mumbai, India.
| |
Collapse
|
3
|
Luo H, Feng Y, Wang F, Lin Z, Huang J, Li Q, Wang X, Liu X, Zhai X, Gao Q, Li L, Zhang Y, Wen J, Zhang L, Niu T, Zheng Y. Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma. Cancer Lett 2023; 565:216218. [PMID: 37149018 DOI: 10.1016/j.canlet.2023.216218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2023] [Revised: 04/30/2023] [Accepted: 05/02/2023] [Indexed: 05/08/2023]
Abstract
Multiple myeloma (MM) is an incurable malignancy of plasma cells. Ivermectin is a US Food and Drug Administration-approved drug for antiparasitic use. Here, we showed that ivermectin exerted anti-MM effects and significantly synergized with proteasome inhibitors in vitro and in vivo. Ivermectin alone exhibited mild anti-MM activity in vitro. Further investigation suggested that ivermectin inhibited proteasome activity in the nucleus by repressing the nuclear import of proteasome subunits, such as PSMB5-7 and PSMA3-4. Therefore, ivermectin treatment caused the accumulation of ubiquitylated proteins and the activation of the UPR pathway in MM cells. Furthermore, ivermectin treatment caused DNA damage and DNA damage response (DDR) signaling pathway activation in MM cells. Ivermectin and bortezomib exhibited synergized anti-MM activity in vitro. The dual-drug treatment resulted in synergistic inhibition of proteasome activity and increased DNA damage. An in vivo study using a human MM cell line xenograft mouse model showed that ivermectin and bortezomib efficiently repressed MM tumor growth in vivo, while the dual-drug treatment was well tolerated by experimental animals. Overall, our results demonstrated that ivermectin alone or cotreated with bortezomib might be promising in MM treatment.
Collapse
Affiliation(s)
- Hongmei Luo
- Department of Hematology, West China Hospital, Sichuan University, China
| | - Yu Feng
- Department of Hematology, West China Hospital, Sichuan University, China
| | - Fangfang Wang
- Department of Hematology, West China Hospital, Sichuan University, China
| | - Zhimei Lin
- Department of Hematology, West China Hospital, Sichuan University, China; Department of Hematology, The Affiliated Hospital of Chengdu University, China
| | - Jingcao Huang
- Department of Hematology, West China Hospital, Sichuan University, China
| | - Qian Li
- Department of Hematology, West China Hospital, Sichuan University, China
| | - Xin Wang
- Department of Hematology, West China Hospital, Sichuan University, China
| | - Xiang Liu
- Department of Hematology, West China Hospital, Sichuan University, China
| | - Xinyu Zhai
- Department of Hematology, West China Hospital, Sichuan University, China
| | - Qianwen Gao
- Department of Hematology, West China Hospital, Sichuan University, China
| | - Lingfeng Li
- Department of Hematology, West China Hospital, Sichuan University, China
| | - Yue Zhang
- Department of Hematology, West China Hospital, Sichuan University, China
| | - Jingjing Wen
- Department of Hematology, West China Hospital, Sichuan University, China; Department of Hematology, Mian-yang Central Hospital, China
| | - Li Zhang
- Department of Hematology, West China Hospital, Sichuan University, China
| | - Ting Niu
- Department of Hematology, West China Hospital, Sichuan University, China.
| | - Yuhuan Zheng
- Department of Hematology, West China Hospital, Sichuan University, China.
| |
Collapse
|
4
|
Zhang M, Zhou Z, Liu Z, Liu F, Zhao C. Exploring the potential biomarkers for prognosis of glioblastoma via weighted gene co-expression network analysis. PeerJ 2022; 10:e12768. [PMID: 35111402 PMCID: PMC8781321 DOI: 10.7717/peerj.12768] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2021] [Accepted: 12/17/2021] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND Glioblastoma (GBM) is the most common malignant tumor in the central system with a poor prognosis. Due to the complexity of its molecular mechanism, the recurrence rate and mortality rate of GBM patients are still high. Therefore, there is an urgent need to screen GBM biomarkers to prove the therapeutic effect and improve the prognosis. RESULTS We extracted data from GBM patients from the Gene Expression Integration Database (GEO), analyzed differentially expressed genes in GEO and identified key modules by weighted gene co-expression network analysis (WGCNA). GSE145128 data was obtained from the GEO database, and the darkturquoise module was determined to be the most relevant to the GBM prognosis by WGCNA (r = - 0.62, p = 0.01). We performed enrichment analysis of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) to reveal the interaction activity in the selected modules. Then Kaplan-Meier survival curve analysis was used to extract genes closely related to GBM prognosis. We used Kaplan-Meier survival curves to analyze the 139 genes in the darkturquoise module, identified four genes (DARS/GDI2/P4HA2/TRUB1) associated with prognostic GBM. Low expression of DARS/GDI2/TRUB1 and high expression of P4HA2 had a poor prognosis. Finally, we used tumor genome map (TCGA) data, verified the characteristics of hub genes through Co-expression analysis, Drug sensitivity analysis, TIMER database analysis and GSVA analysis. We downloaded the data of GBM from the TCGA database, the results of co-expression analysis showed that DARS/GDI2/P4HA2/TRUB1 could regulate the development of GBM by affecting genes such as CDC73/CDC123/B4GALT1/CUL2. Drug sensitivity analysis showed that genes are involved in many classic Cancer-related pathways including TSC/mTOR, RAS/MAPK.TIMER database analysis showed DARS expression is positively correlated with tumor purity (cor = 0.125, p = 1.07e-02)), P4HA2 expression is negatively correlated with tumor purity (cor =-0.279, p = 6.06e-09). Finally, GSVA analysis found that DARS/GDI2/P4HA2/TRUB1 gene sets are closely related to the occurrence of cancer. CONCLUSION We used two public databases to identify four valuable biomarkers for GBM prognosis, namely DARS/GDI2/P4HA2/TRUB1, which have potential clinical application value and can be used as prognostic markers for GBM.
Collapse
Affiliation(s)
- Mengyuan Zhang
- Department of Neurology and Stroke Center, The First Hospital of China Medical University, Shenyang, China
| | - Zhike Zhou
- Department of Geriatrics, The First Hospital of China Medical University, Shenyang, China
| | - Zhouyang Liu
- Department of Neurology and Stroke Center, The First Hospital of China Medical University, Shenyang, China
| | - Fangxi Liu
- Department of Neurology and Stroke Center, The First Hospital of China Medical University, Shenyang, China
| | - Chuansheng Zhao
- Department of Neurology and Stroke Center, The First Hospital of China Medical University, Shenyang, China
| |
Collapse
|
5
|
Osteosarcoma cell proliferation suppression via SHP-2-mediated inactivation of the JAK/STAT3 pathway by tubocapsenolide A. J Adv Res 2022; 34:79-91. [PMID: 35024182 PMCID: PMC8655134 DOI: 10.1016/j.jare.2021.06.004] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Revised: 05/19/2021] [Accepted: 06/08/2021] [Indexed: 11/25/2022] Open
Abstract
Introduction Previously, we have reported a withanolide-type steroid, named tubocapsenolide A (TA), which shows potent anti-proliferative activity in several cancer cell lines. However, its inhibitory effect on the Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) pathway and therapeutic potential on osteosarcoma have not been reported. Objectives In the present study, we aimed to investigate the effect and molecular mechanism of TA in osteosarcoma. Methods The biological functions of TA in U2OS cells were investigated using colony formation, 5-ethynyl-20-deoxyuridine (EDU) staining, and cell cycle/apoptosis assays. The interaction between TA and Src homology 2 phosphatase 2 (SHP-2) was detected by enzyme activity and validated by target-identification methods such as drug affinity responsive target stability (DARTS), cellular thermal shift assay (CETSA), and biolayer interferometry (BLI). The in vivo anti-tumor efficacy of TA was analyzed in the xenograft tumor model. Western blotting analysis was performed to detect the protein expression levels. Results TA exhibited antitumor activity against osteosarcoma both in vitro and in vivo by regulating the JAK/STAT3 signaling pathway. Mechanically, TA interacted with SHP-2 directly and activated its phosphatase activity. Importantly, protein tyrosine phosphatase (PTP) inhibitor, SHP-2 inhibitor, and SHP-2 siRNA could reverse the inhibitory effect of TA on the JAK/STAT3 signaling pathway and restored the TA-induced cell death. Conclusion TA activated the phosphatase activity of SHP-2, which resulted in the inhibition of the JAK/STAT3 pathway and contributed to the antitumor efficacy of TA. Collectively, these findings suggested that TA could serve as a novel therapeutic agent for the treatment of osteosarcoma.
Collapse
|
6
|
Han H, Xu X, Ma Y, Luo Y, Wang Z, Yang M, Wen Z, Zhang Y, Yin T, Zhao Q, Lin H, Lu G, Yang R, Wang X, Qi J, Yang Y. Discovering Podophyllotoxin Derivatives as Potential Anti‐Tubulin Agents: Design, Synthesis and Biological Evaluation. ChemistrySelect 2020. [DOI: 10.1002/slct.202002962] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Hongwei Han
- State Key Laboratory of Pharmaceutical Biotechnology Institute of Plant Molecular Biology School of Life Sciences Nanjing University Nanjing 210023 PR China
| | - Xinhong Xu
- State Key Laboratory of Pharmaceutical Biotechnology Institute of Plant Molecular Biology School of Life Sciences Nanjing University Nanjing 210023 PR China
| | - Yingying Ma
- State Key Laboratory of Pharmaceutical Biotechnology Institute of Plant Molecular Biology School of Life Sciences Nanjing University Nanjing 210023 PR China
| | - Yuelin Luo
- State Key Laboratory of Pharmaceutical Biotechnology Institute of Plant Molecular Biology School of Life Sciences Nanjing University Nanjing 210023 PR China
| | - Zizhen Wang
- State Key Laboratory of Pharmaceutical Biotechnology Institute of Plant Molecular Biology School of Life Sciences Nanjing University Nanjing 210023 PR China
| | - Minkai Yang
- State Key Laboratory of Pharmaceutical Biotechnology Institute of Plant Molecular Biology School of Life Sciences Nanjing University Nanjing 210023 PR China
| | - Zhongling Wen
- State Key Laboratory of Pharmaceutical Biotechnology Institute of Plant Molecular Biology School of Life Sciences Nanjing University Nanjing 210023 PR China
| | - Yahan Zhang
- State Key Laboratory of Pharmaceutical Biotechnology Institute of Plant Molecular Biology School of Life Sciences Nanjing University Nanjing 210023 PR China
| | - Tongming Yin
- Co–Innovation Center for Sustainable Forestry in Southern China MOE Key Laboratory of Forest Genetics and Biotechnology Nanjing Forestry University Nanjing 210037 PR China
| | - Quan Zhao
- State Key Laboratory of Pharmaceutical Biotechnology Institute of Plant Molecular Biology School of Life Sciences Nanjing University Nanjing 210023 PR China
| | - Hongyan Lin
- State Key Laboratory of Pharmaceutical Biotechnology Institute of Plant Molecular Biology School of Life Sciences Nanjing University Nanjing 210023 PR China
| | - Guihua Lu
- State Key Laboratory of Pharmaceutical Biotechnology Institute of Plant Molecular Biology School of Life Sciences Nanjing University Nanjing 210023 PR China
- Co–Innovation Center for Sustainable Forestry in Southern China MOE Key Laboratory of Forest Genetics and Biotechnology Nanjing Forestry University Nanjing 210037 PR China
- School of Life Sciences Huaiyin Normal University Huaian 223300 PR China
| | - Rongwu Yang
- State Key Laboratory of Pharmaceutical Biotechnology Institute of Plant Molecular Biology School of Life Sciences Nanjing University Nanjing 210023 PR China
| | - Xiaoming Wang
- State Key Laboratory of Pharmaceutical Biotechnology Institute of Plant Molecular Biology School of Life Sciences Nanjing University Nanjing 210023 PR China
| | - Jinliang Qi
- State Key Laboratory of Pharmaceutical Biotechnology Institute of Plant Molecular Biology School of Life Sciences Nanjing University Nanjing 210023 PR China
- Co–Innovation Center for Sustainable Forestry in Southern China MOE Key Laboratory of Forest Genetics and Biotechnology Nanjing Forestry University Nanjing 210037 PR China
| | - Yonghua Yang
- State Key Laboratory of Pharmaceutical Biotechnology Institute of Plant Molecular Biology School of Life Sciences Nanjing University Nanjing 210023 PR China
- Co–Innovation Center for Sustainable Forestry in Southern China MOE Key Laboratory of Forest Genetics and Biotechnology Nanjing Forestry University Nanjing 210037 PR China
| |
Collapse
|